# Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer

> **NCT05318794** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Imperial College London** · enrollment: 20 (estimated)

## Conditions studied

- Gastric Cancer
- Peritoneal Metastases
- Chemotherapy Effect

## Interventions

- **DRUG:** Doxorubicin and Cisplatin

## Key facts

- **NCT ID:** NCT05318794
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11
- **Primary completion:** 2025-07
- **Final completion:** 2030-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05318794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05318794, "Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05318794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*